Early Access Programmes: Challenges and Considerations

 In this Pharma IQ interview, Jose Ricardo Perez, Senior Medical Director at Novartis, highlights the biggest considerations for someone potentially looking at a new Early Access programme (EAP) and the key regulatory differences between the USA and Europe. Perez also reveals his top tips for someone looking to implement an early access programme.Pharma IQ: What does the current marketplace look like for early access programmes? Is this a growing area?J Ricardo Perez: I personally... To continue reading this story Click Here